P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

December 2005

Features

Blood Management

New Research Emerges on Dangers of Blood Loss

Mr. Alexander describes the importance of blood-conservation strategies, including the use of drugs, that can be beneficial during procedures such as transfusions and coronary artery bypass grafting.
Walter Alexander, MS

Meeting Highlights

American Society of Hematology State-of-the-Art Symposium: Myeloma and Lymphoma: Recent Advances in Biology and Therapy

Progress is being made in the way tumors are being targeted by agents such as lenalidomide, bortezomib, rituximab, and a variety of other novel chemotherapeutic regimens.
Marvin M. Goldenberg, PhD, RPh, MS

16th Annual Meeting of the North American Menopause Society

The Prescotts discuss hormonal replacement therapy; lasofoxifene for vaginal atrophy; testosterone for low libido; alendronate, transdermal estrogen, risedronate, and ibandronate for osteoporosis; and the transdermal oxybutynin patch for overactive bladder.
Lawrence M. Prescott, PhD, and Sharon L. Prescott

Continuing Education Credit

To Abruptly Cross Over or Not: That Is the Question in SSRI Conversion

When switching patients from one selective serotonin reuptake inhibitor to another, health care providers need to consider several factors, namely, the pharmacokinetic profile of the current drug, the possibility of serotonin syndrome, and withdrawal symptoms.
Kristin Zerumsky, PharmD, Rae Ann Maxwell, RPh, PhD, and Nicole T. Ansani, PharmD

Departments

PPIs and Suppressing Surprise

David Nash, MD, MBA, questions whether the widespread use of proton pump inhibitors is creating new problems, including the risk of Clostridium difficile infection.
David B. Nash, MD, MBA

Prescription: Washington

E-prescribing Standards: A Prescription for Paralysis? Medicare Excludes RxHub Formulary Protocols

Stephen Barlas discusses problems with Medicare’s interim electronic prescribing standards, which exclude protocols that would have allowed PBMs and physicians to exchange important information.
Stephen Barlas

Medication Errors

Bad “Marks” for Order Communication

Matthew Grissinger, RPh, FASCP, discusses the dangers of stray and intentional marks on prescription order forms.
Matthew Grissinger, RPh, FASCP

Drug Forecast

Advances in Proton Pump Inhibitor Therapy: An Immediate-Release Formulation of Omeprazole

Dr. Small reviews an immediate-release formulation of the proton pump inhibitor omeprazole (Zegerid®) for the treatment of gastric acid–related disorders.
Ralph E. Small, PharmD

New Drugs/Drug News/New Medical Devices

P&T presents the latest information about FDA approvals, drug indications, industry updates, and new devices.